Terza Missione | Trial Clinici

Sponsor: Patara Pharma; descrizione: Randomized, double blind, placebo-controlled, cross-over design efficacy and safety study with PA-101 in patients with indolent systemic mastocytosis

Sponsor: BioCryst Pharmaceuticals - A multicenter, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX-4161 for 12 weeks as an oral prophylactic treatment for attacks of hereditary angioedema

Open-label - pazienti arruolati: 7

 Tralokinumab in pazienti asmatici